The Role of MMP7 and Its Cross-Talk with the FAS/FASL System during the Acquisition of Chemoresistance to Oxaliplatin

Background The efficacy of oxaliplatin in cancer chemotherapy is limited by the development of drug resistance. MMP7 has been related to the loss of tumor cell response to cytotoxic agents although the exact mechanism is not fully understood. Moreover, MMP7 is an independent prognosis factor for survival in patients with colorectal cancer. The aim of the present study was to analyze the role of MMP7 and its cross-talk with the Fas/FasL system during the acquisition of oxaliplatin resistance in colon cancer cells. Principal Findings For this purpose we have developed three different oxaliplatin-resistant cell lines (RHT29, RHCT116 p53+/+, RHCT116 p53−/−) from the parental HT29, HCT116 p53+/+ and HCT116 p53−/− colon cancer cells. MMP7 basal expression was higher in the resistant compared to the parental cell lines. MMP7 was also upregulated by oxaliplatin in both HT29 (p53 mutant) and RHCT116 p53−/− but not in the RHCT116 p53+/+. Inhibition of MMP by 1,10-phenantroline monohydrate or siRNA of MMP7 restores cell sensitivity to oxaliplatin-induced apoptosis in both HT29 and RHCT116 p53−/− but not in the RHCT116 p53+/+. Some of these effects are caused by alterations in Fas receptor. Fas is upregulated by oxaliplatin in colon cancer cells, however the RHT29 cells treated with oxaliplatin showed a 3.8-fold lower Fas expression at the cell surface than the HT29 cells. Decrease of Fas at the plasma membrane seems to be caused by MMP7 since its inhibition restores Fas levels. Moreover, functional analysis of Fas demonstrates that this receptor was less potent in inducing apoptosis in RHT29 cells and that its activation induces MAPK signaling in resistant cells. Conclusions Taking together, these results suggest that MMP7 is related to the acquisition of oxaliplatin-resistance and that its inhibition restores drug sensitivity by increasing Fas receptor. Furthermore, Fas undergoes a change in its functionality in oxaliplatin-resistant cells inducing survival pathways instead of apoptotic signals.

[1]  C. Nadal,et al.  Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients , 2007, International journal of cancer.

[2]  J. Chang,et al.  Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil , 2007, British Journal of Cancer.

[3]  M. Peter,et al.  Corrigendum to “Does CD95 have tumor promoting activities?” [Biochim. Biophys. Acta 1755 (2005) 25–36] , 2007 .

[4]  J. Chang,et al.  188 POSTER Combined modalities of resistance in an oxaliplaitin-resistant human gastric cancer cell line with enhanced sensitivity , 2006 .

[5]  L. Ellis,et al.  Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.

[6]  Po-min Chen,et al.  Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. , 2006, Carcinogenesis.

[7]  C. Hallas,et al.  The role of receptor internalization in CD95 signaling , 2006, The EMBO journal.

[8]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[9]  Hiroyuki Yamamoto,et al.  Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer Invasion, Apoptosis, Growth, and Angiogenesis , 2006, Experimental biology and medicine.

[10]  Christopher M Overall,et al.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.

[11]  E. Campo,et al.  Paraffin-Embedded Cell Line Microarray (PECLIMA): Development and Validation of a High-Throughput Method for Antigen Profiling of Cell Lines , 2005, Pathobiology.

[12]  H. Yamamoto,et al.  Tumour matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers , 2005, Gut.

[13]  M. Peter,et al.  Does CD95 have tumor promoting activities? , 2005, Biochimica et biophysica acta.

[14]  M. Peter,et al.  CD95 ligand induces motility and invasiveness of apoptosis‐resistant tumor cells , 2004, The EMBO journal.

[15]  P. Galle,et al.  Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells , 2004, Oncogene.

[16]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Kebin Liu,et al.  Exposure of Human Primary Colon Carcinoma Cells to Anti-Fas Interactions Influences the Emergence of Pre-existing Fas-Resistant Metastatic Subpopulations , 2003, The Journal of Immunology.

[18]  B. Fingleton,et al.  Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. , 2002, Archives of biochemistry and biophysics.

[19]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[20]  B. Fingleton,et al.  Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. , 2002, Cancer research.

[21]  B. Desoize,et al.  Particular aspects of platinum compounds used at present in cancer treatment. , 2002, Critical reviews in oncology/hematology.

[22]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[23]  Y. Mizutani,et al.  Significance of serum soluble fas ligand in patients with bladder carcinoma , 2001, Cancer.

[24]  H. Mellstedt,et al.  Increased serum levels of soluble Fas in progressive B‐CLL , 2001, European journal of haematology.

[25]  H. Yamamoto,et al.  Association of trypsin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma , 2001, Cancer.

[26]  K. Hirata,et al.  Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  I. Stamenkovic,et al.  Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. , 2001, Cancer research.

[28]  B. Fingleton,et al.  Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. , 2001, Neoplasia.

[29]  J. Houghton,et al.  p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[31]  N. Nonomura,et al.  Soluble Fas in serum from patients with renal cell carcinoma. , 2000, Urology.

[32]  H. Yamamoto,et al.  Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. , 1999, Cancer research.

[33]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[34]  L. Matrisian,et al.  The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. , 1998, Cancer research.

[35]  R. Klebe,et al.  Overview of matrix metalloproteinase expression in cultured human cells. , 1998, Matrix biology : journal of the International Society for Matrix Biology.

[36]  L. Matrisian,et al.  Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.

[37]  E. Solary,et al.  Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. , 1997, Journal of the National Cancer Institute.

[38]  P. Baeuerle,et al.  Selective recognition of the activated form of transcription factor NF-kappa B by a monoclonal antibody. , 1995, Biological chemistry Hoppe-Seyler.

[39]  Jack P. Witty,et al.  Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. , 1994, Cancer research.